Axonics® expands into stress urinary incontinence with the acquisition of bulkamid®

Irvine, calif.--(business wire)--axonics modulation technologies, inc. (nasdaq: axnx), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (snm) devices for the treatment of urinary and bowel dysfunction, today announced that it has acquired privately-held contura ltd. and its flagship product, bulkamid, a best-in-class urethral bulking agent for women with stress urinary incontinence (sui). axonics acquired london-based contura ltd. f
AXNX Ratings Summary
AXNX Quant Ranking